Esperion Therapeutics Inc (LTS:0IIM)
$ 2.135 0.1668 (8.47%) Market Cap: 424.83 Mil Enterprise Value: 504.66 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 50/100

Esperion Therapeutics Inc to Discuss the Approval and Upcoming Commercial Launch of Nexlizet Conference Call Transcript

Feb 27, 2020 / 01:00PM GMT
Release Date Price: $50.1 (-21.32%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the NEXLIZET FDA approval conference call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Mr. Alex Schwartz, Head of Investor Relations. Please go ahead, sir.

Alexander Duke Schwartz
Esperion Therapeutics, Inc. - Senior Director of IR

Thank you, Olivia. Good morning, ladies and gentlemen, and welcome. I'm Alex Schwartz, Head of Investor Relations at Esperion. (Operator Instructions)

Joining me for today's call are Tim Mayleben, President and Chief Executive Officer; Ashley Hall, Chief Development Officer; Mark Glickman, Chief Commercial Officer; Rick Bartram, Chief Financial Officer; and Bill Sasiela, Senior Vice President of Clinical Development.

I'd like to remind callers that the information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot